Riboxx Pharmaceuticals and China National Biotec Group Company Limited initiate a collaboration
Radebeul, Germany and Beijing, China, 5th March 2013 – Riboxx Pharmaceuticals GmbH (Riboxx) and China National Biotec Group Company Limited (CNBG) today announced that they have initiated a research collaboration to evaluate Riboxxim®, a TLR3 agonist from Riboxx, with an antigen of CNBG against one of the world’s deadliest infectious diseases.
During the term of the research collaboration, Riboxx will provide access to Riboxxim® to enable CNBG to perform an evaluation in conjunction with CNBG’s antigen against the disease target.
Dr. Jacques Rohayem, CEO of Riboxx said:
“We are delighted to initiate this collaboration with CNBG, which is one of the leading developers of vaccines against serious infectious diseases. Our TLR3 agonist has the potential to increase the efficacy of the antigen and provide a safe but highly effective immune response against the disease.”
Xie Guilin, Vice President of CNBG said:
“The collaboration with Riboxx is designed to evaluate the potential of Riboxxim as an effective adjuvant to enhance the performance of our antigen. This combination has the potential to deliver effective immunization against a deadly disease that is inadequately treated at present.”
About Riboxx Pharmaceuticals GmbH
Riboxx Pharmaceuticals GmbH is a company focused on the development of molecules targeted to Toll-like Receptors (TLRs), with a direct application as vaccine adjuvants. The company engineers and manufactures Riboxxim, agonists of TLR-3, to the highest possible quality standards. Today, Riboxx has on-going collaborations with both academic and industrial partners to advance the application of Riboxxim in vaccination and immunotherapy. The company is headquartered in Radebeul, Germany. More information can be found at www.riboxx-pharma.com .
The proprietary TLR3 agonist of Riboxx, Riboxxim®, is a class of synthetic, highly pure and precisely defined nucleic acids molecules manufactured by TENPORA®, a proprietary process of Riboxx. These molecules are capable of triggering innate immune responses through TLR-3 activation, enabling novel immunization approaches both in prophylactic vaccines (e.g. against infections) and in therapeutic vaccines (e.g. against cancer).
China National Biotec Group Company Limited (CNBG), is a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM). As the first manufacturer of vaccines and blood products in China and with 6 Biological Products Institutes in house, they have been devoted to the research, development, production and supply of biological products since 1919. The development of CNBG Corporation represents the history of Chinese biological products industry. In the past century, they made great contribution in China’s endeavor of eradiating smallpox, eliminating polio, reducing the incidence of various serious infectious diseases, supplied billions of doses of vaccines and therapeutic biological to the country, thus, and safeguarding the health of the world’s largest population. More information can be found at http://en.cnbg.com.cn/
For Further Information, please contact:
Dr. Jacques Rohayem
Founder and CEO
T: +49 351 833 6010
Dr. Xie Guilin